News and Updates

iVeena promotes Michael Burr Vice President, Product development

10 February 2015

Mr. Burr has over 7 years of experience in ocular drug delivery and device development. From 2008 to 2009, Mr. Burr was a fellow at the Lassonde Entrepreneur Institute. Beginning in June 2009, Mr. Burr was hired as a Drug Delivery Scientist at iVeena where he oversaw drug delivery research & development in neovascular age-related macular degeneration and glaucoma. Upon promotion to Vice President of Product Development in 2015, Mr. Burr now oversees the commercial development of iVeena’s pipeline. Mr. Burr holds Bachelor’s and Master’s degrees in biomedical engineering from the University of Utah and also holds an M.B.A. from the David Eccles School of Business at the University of Utah.

iVeena publishes Proof of Concept studies for Post Surgery Cataract Inflammation products

20 November 2013

iVeena has demonstrated safety and efficacy in 42 rabbit eyes in treating post-surgical inflammation and retinal thickening (as measured by optical coherence tomography). iVeena has also demonstrated appropriate and desired first-order release kinetics of dexamethasone. iVeena has been able to reproducibly manufacture implants using a method of hot-melt extrusion that is scalable, operable with our equipment, in a clean-room GMP environment, and sterilizable with e-beam radiation and package-able with a vacuum sealed pouch.